CD274 and neoplasm: In contrast, women experience higher survival benefits from the addition of chemotherapy to anti-PD-1/PD-L1 antibodies, likely due to its ability to increase the mutational burden and neoantigenic load of female tumours, which are statistically significantly lower than in male tumours [42,56].